Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study

Travel Medicine and Infectious Disease

Volumn 12, Issue 2, 2014, Pages 134-142

  Askling, Helena H ^a,b   Rombo, Lars ^a,c   Van Vollenhoven, Ronald ^a   Hallén, Ingemar ^d   Thörner, Åke ^e   Nordin, Margareta ^f   Herzog, Christian ^g   Kantele, Anu ^h,i  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Dept of Communicable Diseases Control and Prevention ^*  (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d CENTRAL HOSPITAL   (Sweden)

^e Mälar Hospital Eskilstuna   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Hepatitis A; Immunosuppression; Rheumatoid arthritis; TNF inhibitors; Vaccination

Indexed keywords

ADALIMUMAB; ETANERCEPT; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; METHOTREXATE; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; FEMALE; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MENINGOENCEPHALITIS; MIDDLE AGED; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RHEUMATOID ARTHRITIS; VACCINATION; VERTIGO; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; HEPATITIS A; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; IMMUNOCOMPROMISED HOST; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTORS;

EID: 84898598795     PISSN: 14778939     EISSN: 18730442     Source Type: Journal    
DOI: 10.1016/j.tmaid.2014.01.005     Document Type: Article

References (35)

1. A. Johnston, J.E. Gudjonsson, H. Sigmundsdottir, B.R. Ludviksson, and H. Valdimarsson The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules Clin Immunol 114 2005 154 163
2. M.C. Kapetanovic, T. Saxne, J.A. Nilsson, and P. Geborek Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients Rheumatology 46 2007 608 611
3. L.B. Gelinck, A.E. van der Bijl, W.E. Beyer, L.G. Visser, T.W. Huizinga, and R.A. van Hogezand et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination Ann Rheum Dis 67 2008 713 716
4. G. Cullen, C. Bader, J.R. Korzenik, and B.E. Sands Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease Gut 61 2012 385 391
5. J.F. Rahier, P. Papay, J. Salleron, S. Sebastian, M. Marzo, L. Peyrin-Biroulet European Crohn's and Colitis Organisation (ECCO) H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy Gut 60 2011 456 462
6. G.Y. Melmed, N. Agarwal, R.W. Frenck, A.F. Ippoliti, P. Ibanez, and K.A. Papadakis et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease Am J Gastroenterol 105 2010 148 154
7. G. Fiorino, L. Peyrin-Biroulet, P. Naccarato, H. Szabò, O.R. Sociale, and S. Vetrano et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study Inflamm Bowel Dis 18 2012 1042 1047
8. M.C. Kapetanovic, C. Roseman, G. Jönsson, L. Truedsson, T. Saxne, and P. Geborek Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors Arthritis Rheum 63 2011 3723 3732
9. O. Elkayam, D. Caspi, T. Reitblatt, D. Charboneau, and J.B. Rubins The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis Semin Arthritis Rheum 33 2004 283 288
10. M.C. Kapetanovic, T. Saxne, A. Sjöholm, L. Truedsson, G. Jönsson, and P. Geborek Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis Rheumatology 45 2006 106 111
11. J.L. Kaine, A.J. Kivitz, C. Birbara, and A.Y. Luo Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab J Rheumatol 34 2007 272 279
12. I. Fomin, D. Caspi, V. Levy, N. Varsano, Y. Shalev, and D. Paran et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers Ann Rheum Dis 65 2006 191 194
13. S. Oren, M. Mandelboim, Y. Braun-Moscovici, D. Paran, J. Ablin, and I. Litinsky et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response Ann Rheum Dis 67 2008 937 941
14. J.J. Kobie, B. Zheng, P. Bryk, M. Barnes, C.T. Ritchlin, and D.A. Tabechian et al. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor Arthritis Res Ther 13 2011 R209
15. S. Mori, Y. Ueki, N. Hirakata, M. Oribe, T. Hidaka, and K. Oishi Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis Ann Rheum Dis 71 2012 2006 2010
16. P.J. Mease, C.T. Ritchlin, R.W. Martin, A.B. Gottlieb, S.W. Baumgartner, and D.J. Burge et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept J Rheumatol 31 2004 1356 1361
17. J. Evison, S. Farese, M. Seitz, D.E. Uehlinger, H. Furrer, and K. Mühlemann Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients Clin Infect Dis 48 2009 1402 1412
18. L.B. Gelinck, A.E. van der Bijl, L.G. Visser, T.W. Huizinga, R.A. van Hogezand, and G.T. Rijkers et al. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine Vaccine 26 2008 3528 3533
19. P.A. Bovier, J. Bock, T.F. Ebengo, G. Frösner, J. Glaus, and C. Herzog et al. Predicted 30-year protection after vaccination with an inactivated virosome hepatitis A vaccine J Med Virol 82 2010 1629 1634
20. N. Orr, E. Klement, D. Gillis, T. Sela, R. Kayouf, and E. Derazne et al. Long-term immunity in young adults after a single dose of inactivated hepatitis A vaccines Vaccine 24 2006 4328 4332
21. P. Schmidtke, P. Habermehl, M. Knuf, C.U. Meyer, R. Sänger, and F. Zepp Cell mediated and antibody immune response to inactivated hepatitis A vaccine Vaccine 23 2005 5127 5132
22. J.C. Victor, A.S. Monto, T.Y. Surdina, S.Z. Suleimenova, G. Vaughan, and O.V. Nainan et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis N Engl J Med 357 2007 1685 1694
23. Centers for Disease Control and Prevention (CDC) Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR 56 2007 1080 1084
24. Centers for Disease Control and Prevention (CDC) Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR 55 RR-7 2006 1 23
25. J.P. Liu, D. Nikolova, and Y. Fei Immunoglobulins for preventing hepatitis A Cochrane Database Syst Rev 2009 CD004181
26. I.R. Willner, M.D. Uhl, S.C. Howard, E.Q. Williams, C.A. Riely, and B. Waters Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States Ann Intern Med 128 1998 111 114
27. V. D'Acremont, C. Herzog, and B. Genton Immunogenicity and safety of a virosomal hepatitis A vaccine (epaxal) in the elderly J Travel Med 13 2006 78 83
28. W. van den Bijllaardt, H.M. Siers, C. Timmerman-Kok, F.G. Pessers, G. Natrop, and J.F. van Baars et al. Seroprotection after hepatitis a vaccination in patients with drug-induced immunosuppression J Travel Med 20 2013 278 282
29. R. Berger, M. Just, and B. Althaus Time course of hepatitis A antibody production after active, passive and active/passive immunization: the results are highly dependent on the antibody test system used J Virol Methods 43 1993 287 297
30. R. Clemens, A. Safary, A. Hepburn, C. Roche, W.J. Stanbury, and F.E. André Clinical experience with an inactivated hepatitis A vaccine J Infect Dis 171 Suppl. 1 1995 S44 S49
31. World Health Organization (WHO) The immunological basis for immunization series Module 18: hepatitis A 2010 Available at: http://whqlibdoc.who.int/ publications/2011/9789241501422-eng.pdf [accessed 18.10.13]
32. B. Genton, V. D'Acremont, H.J. Furrer, C. Hatz, and Louis Loutan Hepatitis A vaccines and the elderly Travel Med Infect Dis 4 2006 303 312
33. S. van Assen, O. Elkayam, N. Agmon-Levin, R. Cervera, M.F. Doran, and M. Dougados et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European league against rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases Autoimmun Rev 10 2011 341 352
34. J.F. Rahier, S. Ben-Horin, Y. Chowers, C. Conlon, P. De Munter, G. D'Haens European Crohn's and Colitis Organisation (ECCO) European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease J Crohns Colitis 3 2009 47 91
35. B.P. Bell Hepatitis A vaccine Semin Pediatr Infect Dis 13 2002 165 173